Elevated neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio and decreased platelet-to-lymphocyte ratio are associated with poor prognosis in multiple myeloma.
Elevated neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio and decreased platelet-to-lymphocyte ratio are associated with poor prognosis in multiple myeloma.
复制标题
中性粒细胞与淋巴细胞比率和单核细胞与淋巴细胞比率升高以及血小板与淋巴细胞比率降低与多发性骨髓瘤的不良预后相关。
DOI：
10.18632/oncotarget.13320
复制
发表时间：
2017-03-21
期刊：
影响因子：
--
通讯作者：
An G
中科院分区：
文献类型：
--
作者：
Shi L;Qin X;Wang H;Xia Y;Li Y;Chen X;Shang L;Tai YT;Feng X;Acharya P;Acharya C;Xu Y;Deng S;Hao M;Zou D;Zhao Y;Ru K;Qiu L;An G
在各种类型的癌症中，炎症标志物升高与不良预后有关；然而，其在多发性骨髓瘤(MM)中的临床意义很少被探讨。本研究探讨MM患者中性粒细胞/淋巴细胞比率(NLR)、血小板/淋巴细胞比率(PLR)和单核细胞/淋巴细胞比率(MLR)与预后的关系。治疗前用全血计数计算NLR、PLR和MLR。生存评估采用Kaplan-Meier曲线和多因素Cox比例模型。结果表明，新诊断的MM患者具有高NLR和MLR的特点。NLR和MLR升高以及PLR降低与不良的临床生物学特征相关。采用4(NLR)、100(PLR)和0.3(MLR)的临界值，升高的NLR、MLR和降低的PLR对预后有负面影响。重要的是，NLR升高和PLR降低是无进展生存的独立预后因素。因此，升高的NLR和MLR以及降低的PLR预示着MM患者较差的临床结果，并可作为经济有效且容易获得的预后生物标志物。
Elevated inflammatory markers are associated with poor outcomes in various types of cancers; however, their clinical significance in multiple myeloma (MM) have seldom been explored. This study investigated the prognostic relevance of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR) in MM. Totally 559 MM patients were included in this study. NLR, PLR and MLR were calculated from whole blood counts prior to therapy. Kaplan-Meier curves and multivariate Cox proportional models were used for the evaluation of the survival. It has shown that newly diagnosed MM patients were characterized by high NLR and MLR. Elevated NLR and MLR and decreased PLR were associated with unfavorable clinicobiological features. Applying cut-offs of 4 (NLR), 100 (PLR) and 0.3 (MLR), elevated NLR, MLR and decreased PLR showed a negative impact on outcome. Importantly, elevated NLR and decreased PLR were independent prognostic factors for progression-free survival. Thus, elevated NLR and MLR, and decreased PLR predict poor clinical outcome in MM patients and may serve as the cost-effective and readily available prognostic biomarkers.